SCHEMBL3650348

SCHEMBL3650348

O=S(=O)(NC(CO)C(c1cc(F)cc(F)c1)C(F)(F)F)c1ccc(Cl)s1

nearest known ligand 0.67

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
PSEN1 P49768 5/20 0.67
PSEN2 P49810 5/20 0.67
APH1B Q8WW43 5/20 0.67
NCSTN Q92542 5/20 0.67
APH1A Q96BI3 5/20 0.67
PSENEN Q9NZ42 5/20 0.67
KMT2A Q03164 3/20 0.34
HTT P42858 2/20 0.34
SMN1; SMN2 Q16637 2/20 0.34
MEN1 O00255 1/20 0.34
TSHR P16473 1/20 0.34
ALDH1A1 P00352 2/20 0.34
MAPT P10636 1/20 0.34
PGAM1 P18669 1/20 0.34
GAA P10253 1/20 0.33
HPGD P15428 1/20 0.33
BMP1 P13497 1/20 0.33
PPARG P37231 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3649274 1.00 PSEN1 (0.67) PSEN1PSEN2APH1BNCSTNAPH1A
SCHEMBL3654450 1.00 PSEN1 (0.67) PSEN1PSEN2APH1BNCSTNAPH1A
SCHEMBL4308731 1.00 PSEN1 (0.67) PSEN1PSEN2APH1BNCSTNAPH1A
SCHEMBL3649278 1.00 PSEN1 (0.67) PSEN1PSEN2APH1BNCSTNAPH1A
SCHEMBL3693711 0.90 PSEN1 (0.64) PSEN1PSEN2APH1BNCSTNAPH1A
SCHEMBL3693709 0.90 PSEN1 (0.64) PSEN1PSEN2APH1BNCSTNAPH1A
SCHEMBL4304789 0.90 PSEN1 (0.64) PSEN1PSEN2APH1BNCSTNAPH1A
SCHEMBL3649815 0.90 PSEN1 (0.69) PSEN1PSEN2APH1BNCSTNAPH1A
SCHEMBL3649812 0.90 PSEN1 (0.69) PSEN1PSEN2APH1BNCSTNAPH1A
SCHEMBL4302273 0.90 PSEN1 (0.69) PSEN1PSEN2APH1BNCSTNAPH1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2193117-A1 INHIBITORS OF BETA AMYLOID PRODUCTION Wyeth a Corporation of the State of Delaware (US) 2010-06-09 EP claimed
US-20090023801-A1 INHIBITORS OF BETA AMYLOID PRODUCTION WYETH (US) 2009-01-22 US claimed
WO-2009012205-A1 INHIBITORS OF BETA AMYLOID PRODUCTION WYETH (US) 2009-01-22 WO claimed
EP-2193117-A1 INHIBITORS OF BETA AMYLOID PRODUCTION Wyeth a Corporation of the State of Delaware (US) 2010-06-09 EP disclosed
US-20090023801-A1 INHIBITORS OF BETA AMYLOID PRODUCTION WYETH (US) 2009-01-22 US disclosed
WO-2009012205-A1 INHIBITORS OF BETA AMYLOID PRODUCTION WYETH (US) 2009-01-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090023801-A1 INHIBITORS OF BETA AMYLOID PRODUCTION GYS1, APP, PSEN1 PSEN1 3/4885PSEN2 5/4885APH1B 29/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.